Data Support Prognostic Utility of aBSI as an Imaging Biomarker for Survival in Patients with Castration-Resistant Prostate Cancer
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) have been published online in JAMA Oncology.
The vast majority of men with CRPC have bone metastases. Bone scan is the standard imaging modality in these patients. Bone scans indirectly assess tumor activity by measuring bone mineral turnover. The Bone Scan Index quantifies the prostate cancer disease burden shown on a bone scan. Employing Artificial Intelligence, aBSI automatically calculates the Bone Scan Index. aBSI permits a faster quantitative assessment of tumor burden compared to manual BSI and is highly reproducible.
The study, entitled, “Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer," establishes the prognostic value of aBSI as a potential biomarker for survival in patients with bone-metastatic CRPC. The study demonstrated that in these patients, aBSI was associated with overall survival and prostate cancer-specific survival (p<0.001), time to symptomatic progression (p<0.001), and time to opiate use for cancer pain (p<0.001).
“There is a significant need for a tool that can reliably and automatically analyze bone scans, provide clinically meaningful data, and reduce the uncertainty associated with the current practice of manual interpretation of these critical scans. This aBSI should ultimately improve how we approach treatment decisions and measure the benefits of such treatments for patients with metastatic castration resistant prostate cancer,” said Andrew Armstrong, MD ScM FACP, Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology Duke Cancer Institute, Duke University, Durham, NC. “The data from this large-scale prospective study validate the use of aBSI as an independent prognostic imaging biomarker for survival and support its potential utility as an objective tool to evaluate a patient’s response and resistance to therapy over time.” Ongoing studies are evaluating changes in aBSI in response to therapies in prostate cancer, which may provide benchmarks for defining response/progression in the clinic.
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
This press release contains projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA; market acceptance for approved products; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including those risk factors included in its Annual Report on Form 10-K for the annual period ended December 31, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Information on or accessed through our website or social media sites is not included in the company's SEC filings.